No Picture

Manufacturing roundup: AGC Biologics to manufacture diabetes therapy; Cambrex caps acquisition of Snapdragon Chemistry

The Washington-based CDMO AGC Biologics has been tapped to manufacture the type 1 diabetes treatment Tzield from Provention Bio. AGC Biologics will produce Tzield at its Seattle protein biologics site. It was chosen after AGC […]